Symptoms and General Pathology

All Conditions

Nervous System Diseases

Neoplasms

Heart and Blood Diseases

Behaviors and Mental Disorders

Immune System Diseases

Syndrome

Migraine Disorders

Brain Neoplasms

Parkinson Disease

Stroke

Cognitive Dysfunction

Epilepsy

Sclerosis

Multiple Sclerosis

Psychomotor Agitation

Restless Legs Syndrome

Autoimmune Diseases

Demyelinating Autoimmune Diseases, CNS

Autoimmune Diseases of the Nervous System

Demyelinating Diseases

Cognition Disorders

Neurocognitive Disorders

Mental Disorders

Psychotic Disorders

Parasomnias

Sleep Disorders, Intrinsic

Dyssomnias

Sleep Wake Disorders

Analgesics

Psychotropic Drugs

All Drugs and Chemicals

Platelet Aggregation Inhibitors

Anti-Arrhythmia Agents

Antihypertensive Agents

Vasodilator Agents

Anti-Inflammatory Agents

Antineoplastic Agents

Channel Blockers

Anticonvulsants

Central Nervous System Depressants

Antipyretics

Antirheumatic Agents

Fibrinolytic Agents

Nootropic Agents

Neuroprotective Agents

Anti-Dyskinesia Agents

Antiemetics

Gastrointestinal Agents

Hypoglycemic Agents

Vasoconstrictor Agents

Other Dietary Supplements

Duloxetine Hydrochloride

Clopidogrel

Propranolol

Prednisolone

Pregabalin

Aspirin

Amitriptyline

Donepezil

Levetiracetam

Rivastigmine

Valproic Acid

Pramipexole

Dexpramipexole

Methylprednisolone

Methylprednisolone Acetate

Methylprednisolone Hemisuccinate

Prednisolone acetate

Prednisolone hemisuccinate

Prednisolone phosphate

Topiramate

Memantine

Rotigotine

Lamotrigine

Zolmitriptan

Sumatriptan

Rizatriptan

Omega 3 Fatty Acid

The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.

brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).

Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)

The investigators will conduct at NorthShore University HealthSystem pragmatic trials using the EMR for 10 common neurological disorders. They will demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and outcomes data capture at the point of care using the EMR. They will identify the most effective treatments for common neurological disorders and seek replication by the NPBRN.

The goals of the proposed research are to advance quality improvement and practice based research in Neurology using the electronic medical record (EMR). The American Academy of Neurology (AAN) has published evidence-based guidelines, quality improvement measures, and resources for several neurological disorders. However, the AAN guidelines and measures have not been implemented routinely and benchmark data are lacking. There are few EMR tools available to standardize neurology office visits according to Best Practices, to provide alerts when neurological care is deviating from AAN guidelines, to capture data regarding adherence to AAN or other quality parameters, to measure the effects of compliance with guidelines on outcomes, or to share longitudinal data and to compare effectiveness of care across neurological practices. The Department of Neurology at NorthShore University HealthSystem (NorthShore) has built into its commercial EMR "Epic" structured clinical documentation support (SCDS) and clinical decision support (CDS) tools that standardize care, write progress notes, and capture up to 1,000 discrete and cascading fields of neurological data per office visit. However, these EMR tools have not been disseminated for use by other Neurology practices or for data sharing, and presently do not support clinical trials. Pragmatic trials using EMRs would enable comparisons of treatments at the point of care. To address gaps in quality improvement and practice based research in Neurology, the investigators are proposing to the Agency for Healthcare Research and Quality (AHRQ) a project with the specific aims: 1) To create a Neurology Practice Based Research Network (NPBRN). The NorthShore site will share SCDS and CDS tools for 10 common neurological disorders (brain tumors, epilepsy, migraine, mild cognitive impairment, mild traumatic brain injury, multiple sclerosis, neuropathy, Parkinson's disease, restless legs syndrome, and stroke) with seven other Department of Neurology that also use the Epic EMR platform (eight sites total). 2) To conduct at NorthShore pragmatic trials using the EMR for 10 common neurological disorders. The investigators will demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and outcomes data capture at the point of care using the EMR. They will identify the most effective treatments for common neurological disorders and seek replication by the NPBRN. The aims are innovative because the investigators will use the EMR to hardwire quality and outcomes research in Neurology. They will individualize medicine at the point of care by conducting pragmatic trials using subgroup based adaptive designs, comparing the effectiveness of available treatments for common neurological disorders. The aims are significant because they are studying several neurological disorders, a leading cause of healthcare burden worldwide. They will create a national practice based network to improve health care quality by accelerating implementation of patient-centered outcomes research in Neurology using the EMR, and evidence to make health care safer and to improve health care efficiency. NOTE: This ClinicalTrials.gov registration relates to Aim 2 of the project (pragmatic trials using the EMR). Aim 1 is an observational study only (quality improvement, comparative effectiveness research).

Quality Improvement and Practice Based Research in Neurology Using the EMR

Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record

NorthShore University HealthSystem

Senior Clinician Educator, Department of Neurology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Quality Improvement and Practice Based Research in Neurology Using the EMR	NCT02670161	Brain Tumors Epilepsy Migraine Mild Cognitive ... Concussion Multiple Sclero... Neuropathy Parkinson's Restless Legs S... Stroke	Listed for each...	18 Years - 100 Years	NorthShore University HealthSystem
Quality Improvement and Practice Based Research in Neurology Using the EMR	NCT02670161	Brain Tumors Epilepsy Migraine Mild Cognitive ... Concussion Multiple Sclero... Neuropathy Parkinson's Restless Legs S... Stroke	Listed for each...	18 Years - 100 Years	NorthShore University HealthSystem

Spots Global Cancer Trial Database for listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see intervention description)